Psoriasis drug tildrakizumab tested in everyday practice
NCT ID NCT04203693
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study followed 331 adults with moderate-to-severe plaque psoriasis who were treated with tildrakizumab (Ilumetri) as part of their routine care. Researchers tracked how much the skin cleared and how quality of life improved over up to two years. The goal was to see if the drug works as well in real life as it did in earlier clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tildrakizumab (Ilumetri)
What this could lead to
If successful, this study could confirm that tildrakizumab works well and is safe for long-term use in everyday medical practice for people with moderate-to-severe plaque psoriasis.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection. It cannot prove cause and effect, and long-term safety data are still limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site 1
Nice, France
-
Investigational Site 1
Augsburg, Germany
-
Investigational Site 1
Arezzo, Italy
-
Investigational Site 10
Cologne, Germany
-
Investigational Site 10
Roma, Italy
-
Investigational Site 11
Lübeck, Germany
-
Investigational Site 11
Roma, Italy
-
Investigational Site 12
München, Germany
-
Investigational Site 12
Rozzano, Italy
-
Investigational Site 13
Merzig, Germany
-
Investigational Site 14
Oberursel, Germany
-
Investigational Site 15
Quedlinburg, Germany
-
Investigational Site 2
Berlin, Germany
-
Investigational Site 2
Brescia, Italy
-
Investigational Site 3
Bochum, Germany
-
Investigational Site 3
Catania, Italy
-
Investigational Site 4
Erlangen, Germany
-
Investigational Site 4
Florence, Italy
-
Investigational Site 5
Greifswald, Germany
-
Investigational Site 5
Genova, Italy
-
Investigational Site 6
Hamburg, Germany
-
Investigational Site 6
Lecce, Italy
-
Investigational Site 7
Halle, Germany
-
Investigational Site 7
Modena, Italy
-
Investigational Site 8
Kiel, Germany
-
Investigational Site 8
Roma, Italy
-
Investigational Site 9
Kiel, Germany
-
Investigational Site 9
Roma, Italy
-
Investigational site 1
Breda, Netherlands
-
Investigator Site 1
Baden, Austria
-
Investigator Site 1
Brussels, Belgium
-
Investigator Site 2
Vienna, Austria
-
Investigator Site 2
Charleroi, Belgium
-
Investigator Site 2
Poitiers, France
-
Investigator Site 3
Genk, Belgium
-
Investigator Site 4
Ghent, Belgium
-
Investigator Site 5
Herstal, Belgium
-
Investigator Site 6
Jette, Belgium
-
Investigator Site 7
Lede, Belgium
-
Investigator Site 8
Leuven, Belgium
-
Investigator Site 9
Mons, Belgium